Biologics in COPD have so far been a story about type 2 inflammation, which restricts them to the minority of patients with raised blood eosinophils. Astegolimab, an anti-ST2 monoclonal antibody targeting the interleukin-33 pathway, was tested without that restriction. This prespecified pooled analysis of the ALIENTO and ARNASA trials covers 2,682 participants with COPD, a history of frequent exacerbations, and current or former smoking, enrolled irrespective of blood eosinophil count and irrespective of chronic bronchitis. They were randomised 1:1:1 to astegolimab 476 mg every two weeks, every four weeks, or placebo for 52 weeks, on top of optimised maintenance therapy.
The two-weekly regimen reduced the annualised rate of moderate or severe exacerbations by 15% (adjusted rate ratio 0.85, 95% CI 0.76 to 0.96, p=0.0077), and the four-weekly regimen by 12% (0.88, 0.78 to 0.99, p=0.0265). Severe exacerbations fell more with the two-weekly dose, by 32% (rate ratio 0.68, 95% CI 0.52 to 0.87, p=0.0028), though that result is described as nominally significant. Tolerability was good.
What makes this potentially practice-changing is not the effect size, which is modest, but the population. A 15% reduction is smaller than the biologics deliver in eosinophilic asthma, and smaller than dupilumab achieves in selected eosinophilic COPD. But it applies to patients with frequent exacerbations who have no type 2 signal and therefore currently have nothing beyond optimised inhaled therapy — a group that includes most people with COPD.
The severe exacerbation result is the more clinically important one and deserves the caution its 'nominally significant' label implies. In a hierarchical testing plan, results tested after the primary endpoint retain formal significance only if the gates above them are passed in order; a nominal result is one that would be significant on its own but does not carry the same protection against a false positive. If a 32% reduction in severe exacerbations holds up, that changes the calculation considerably, because severe exacerbations are what drive admission and mortality.
For Indian practice this is a drug not yet available and, when it arrives, one whose cost will be measured against a 15% relative reduction in a chronic disease with an enormous prevalence. Worth watching for the regulatory decision and the severe exacerbation data; not yet worth planning around.
- Astegolimab reduced moderate or severe exacerbations by 15% with two-weekly dosing, 12% with four-weekly.
- The population was unselected for blood eosinophils — this is the first COPD biologic signal outside type 2 inflammation.
- The 32% reduction in severe exacerbations is nominally significant; wait for confirmation before weighting it heavily.
- The effect size is modest; frame it against optimised inhaled therapy, not as a replacement for it.
- Not yet available; the practical question will be cost against a 15% relative reduction.
The statistics, in plain English
Rate ratios for exacerbations describe how many events happen per patient-year rather than how many patients had one, which suits a condition where the same person exacerbates repeatedly. A rate ratio of 0.85 with an interval of 0.76 to 0.96 excludes no effect but its upper end is close to 1.0, so the true benefit could be as small as 4%. The hierarchical testing plan matters for interpreting the severe exacerbation result: secondary endpoints are tested in a fixed order and only retain protection against false positives while each preceding test passes. 'Nominally significant' means that protection was not in place, so treat 0.68 as promising rather than established.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free